VivoSeq
Oncology

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative

12

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative is an emerging landscape with 12 programs across 7 companies. The most active players are Amgen, Takeda, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

2 programs

Phase 2Takeda logo

Takeda

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2A

Avyxa

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2Roche logo

Roche

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

11programs
Small molecule545%
Protein / enzyme327%
Monoclonal antibody218%
Antibody–drug conjugate19%

Modality classified for 92% of 12 pipeline programs.

Analysis

Trial Status

2

clinical trials

Recruiting2 · 100%

Clinical Trials

Trial Activity

A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative, CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Recruiting·National Cancer Institute (NCI)·Phase 2·NCT03739814·84 enrolled
Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/Leukemia
Recruiting·UUniversity of Washington·Phase 2·NCT06738368·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)